Application of sodium houttuyfonate and sodium new houttuyfonate in treatment of candida auricula infection

By using drugs prepared by Houttuynia cordata and New Houttuynia cordata, the problem of resistance to existing antifungal drugs for Candida auricida infection was solved, and effective inhibition of Candida auricida growth and biofilm formation was achieved. , new treatment options are provided.

CN118924720AInactive Publication Date: 2024-11-12ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411023690.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The treatment of Candida auric infection is difficult, and existing antifungal drugs are resistant to it, making it difficult to effectively inhibit its growth and biofilm formation.

Method used

Using Houttuynia cordata sodium and New Houttuynia cordata sodium as active ingredients to prepare drugs used to inhibit the growth and biofilm formation of Candida auricles, combined with pharmaceutically acceptable excipients to prepare them into different dosage forms, and achieve antibacterial effects through administration. .

Benefits of technology

The minimum inhibitory concentrations of Houttuynia sodium and New Houttuynia sodium are significantly better than those of the existing antifungal drug fluconazole, which can effectively inhibit the growth and biofilm formation of Candida auris, providing a new therapeutic option .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924720A_ABST
    Figure CN118924720A_ABST
Patent Text Reader

Abstract

The invention discloses application of sodium houttuyfonate and sodium new houttuyfonate in treatment of candida auricula infection. Experiments prove that the minimum inhibitory concentrations of sodium houttuyfonate and sodium new houttuyfonate on candida auricula are obviously superior to those of the existing antifungal drug fluconazole, and the sodium houttuyfonate and sodium new houttuyfonate can obviously inhibit the growth of candida auricula and the formation of biological membranes. Based on the discovery, the sodium houttuyfonate and the sodium new houttuyfonate can be used for preparing the candida auricula infection treatment medicine or used for preventing and controlling candida auricula pollution, so that the problems that the existing antifungal medicine is poor in antibacterial effect on candida auricula, obvious in medicine resistance and the like are solved, and a new medicine choice is provided for treatment of candida auricula infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drugs for treating Candida auris infection, and particularly relates to application of houttuyfonate sodium and new houttuyfonate sodium in treating Candida auris infection. Background Art

[0002] Candida auris (commonly known as Candida auris) was first discovered in the external ear canal secretions of a Japanese patient in 2009. Its infection mortality rate is as high as 60%, and it is a recognized "super fungus". "Super fungus" is common in hospital infections. For patients with other diseases in hospitals or nursing homes, "super fungus" is a potentially fatal threat. "Super fungus" has multiple characteristics such as drug resistance and difficulty in accurate detection, making treatment more complicated and difficult.

[0003] Candida auris is a new species of yeast in the subphylum Ascomycota. Under the microscope, oval or oblong yeast spores can be seen. Although it is a yeast-type fungus that reproduces by budding, it is different from most common Candida species and almost never forms short pseudohyphae or germ tubes. Under different culture conditions, Candida auris can show a variety of morphological phenotypes, including round, ovoid, elongated and pseudohyphae-like morphologies.

[0004] The document "Research Progress of Candida auris in Hospital Infection Control" (Chinese Journal of Disinfection, 2021, 38(2):136-139) reported that Candida auris isolated from different regions have significantly different biological characteristics and genotypic characteristics, showing significant geographical differences. According to their kinship, they are mainly divided into four evolutionary branches, namely South Asian strains (India, Pakistan), South African strains, South American strains (Venezuela) and East Asian strains (Japan). Recently, a new potential fifth evolutionary branch was isolated from Iran.

[0005] The paper "Candida auris emergence as a consequence of climate change: impacts on Americas and the need to contain greenhouse gas emissions. Lancet Reg Health Am, 2022, 11: 100250." suggests that the emergence of Candida auris may be related to climate change such as global warming.

[0006] The biggest feature of Candida auris is its strong adaptability to the environment and its ability to survive for a long time. Whether wet or dry, Candida auris can survive for more than 3 weeks on all tested surfaces. In clinical terms, Candida auris can be widely colonized on mucous membranes and skin, and can also be isolated from wounds, rectal swabs, pharyngeal swabs, respiratory tract, urethra and other parts. It can grow on a variety of wet or dry surfaces in hospital environments for at least 7 days, and can survive on plastic surfaces for at least 2 weeks. It can still grow on French Comagat chromogenic medium at 40-42°C and can present white, pink, red or purple colonies. In terms of clinical treatment, most Candida auris are multidrug resistant, including three major categories of antifungal drugs-azole drugs, polyene drugs and echinocandin drugs. Therefore, the treatment of Candida auris infection is difficult, which poses a severe challenge to clinical treatment, and there is an urgent need to develop new targeted therapeutic drugs. Summary of the invention

[0007] In view of the deficiencies in the prior art, the present invention provides a use of houttuyfonate sodium and a new houttuyfonate sodium in the treatment of Candida auris infection.

[0008] The present invention adopts the following technical solutions:

[0009] The first aspect of the present invention provides the use of sodium houttuyfonate and / or new sodium houttuyfonate in the preparation of a medicament for preventing and / or treating Candida auris infection.

[0010] Sodium houttuyfonate (SH), chemically known as sodium decanoyl acetaldehyde bisulfite, is an artificial chemical synthesis of houttuyfonate, an active ingredient in Houttuynia cordata of the Saururaceae plant, and sodium bisulfite. So far, SH has been proven to have the effects of inhibiting inflammation, resisting pathological fibrosis, resisting bacteria, dilating blood vessels, and inhibiting myocardial remodeling. Currently, SH has been used clinically to treat chronic bronchitis, pediatric pneumonia and other respiratory inflammatory diseases, as well as cervicitis, adnexitis, psoriasis, etc.

[0011] Sodium new houttuyfonate (SNH), chemically known as sodium dodecyl acetaldehyde bisulfite, is a chemical synthesis of an aldehyde component in the volatile oil of the whole herb of Houttuynia cordata, a plant of the Saururaceae family. It has the effects of antibacterial disinfection, improving the body's immunity, etc., and is of great significance for the treatment of infectious diseases.

[0012] Houttuyfonate sodium and neohouttuyfonate sodium have the advantages of low toxicity and few side effects.

[0013] According to a specific embodiment of the present invention, Candida auris is resistant to at least one antifungal drug selected from azoles, polyenes, echinocandins and nucleoside analogs.

[0014] According to a specific embodiment of the present invention, the drug is a drug for inhibiting the growth of Candida auris.

[0015] According to a specific embodiment of the present invention, the drug is a drug for inhibiting the formation of Candida auris biofilm.

[0016] According to a specific embodiment of the present invention, the drug uses houttuyfonate sodium and / or neohouttuyfonate sodium as the only active ingredient.

[0017] According to a specific embodiment of the present invention, the drug is a preparation prepared by adding pharmaceutically acceptable excipients with an effective amount of houttuynia cordata sodium and / or new houttuynia cordata sodium as active ingredients. Excipients include but are not limited to any one or a combination of fillers, adhesives, wetting agents, disintegrants, emulsifiers, diluents, lubricants, solvents, cosolvents, solubilizers, stabilizers, surfactants, humectants, antioxidants, pH regulators, colorants, preservatives and aromatics. The preparation is any pharmaceutical dosage form acceptable in pharmacy, including but not limited to any one of tablets, capsules, granules, powders, solutions, gels and injections.

[0018] In order to achieve the purpose of medication and enhance the antibacterial effect, the drug of the present invention can be administered by any known administration method. The daily dosage is within the range of 180 to 270 mg, and the dosage can vary widely according to the desired antibacterial effect, the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form.

[0019] The sodium houttuyfonate, new sodium houttuyfonate or the combination of the present invention can be taken alone or used in combination with other therapeutic drugs or symptomatic drugs. When the sodium houttuyfonate, new sodium houttuyfonate and other therapeutic drugs have synergistic effects, the dosage should be adjusted according to the actual situation.

[0020] The second aspect of the present invention provides the use of sodium houttuyfonate and / or new sodium houttuyfonate in the preparation of additives for preventing and controlling Candida auris contamination. For example, a product containing Candida auris is used to antagonize Candida auris on dry or wet surfaces.

[0021] The beneficial effects of the present invention are:

[0022] The present invention has experimentally confirmed that the minimum inhibitory concentration of houttuynia cordata sodium and new houttuynia cordata sodium against Candida auris is significantly better than that of the existing antifungal drug fluconazole, and can significantly inhibit the growth and biofilm formation of Candida auris. Based on the above findings, houttuynia cordata sodium and new houttuynia cordata sodium can be used to prepare drugs for treating Candida auris infection, or to prevent and control Candida auris contamination, which solves the problems of poor antibacterial effect of current antifungal drugs on Candida auris and obvious drug resistance, and provides a new drug option for the treatment of Candida auris infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 MIC of sodium houttuyfonate, sodium neohouttuyfonate and fluconazole against Candida auris; A: MIC-24h of sodium houttuyfonate against Candida auris; B: MIC-24h of sodium neohouttuyfonate against Candida auris; C: MIC-24h of fluconazole (Flu) against Candida auris; The first and second rows of the 96-well plate in Figures A, B, and C correspond to the effects of the drugs on C1 Candida auris, the third and fourth rows correspond to the effects of the drugs on C2 Candida auris, the fifth and sixth rows correspond to the effects of the drugs on C3 Candida auris, the seventh and eighth rows correspond to the effects of the drugs on C4 Candida auris, the ninetieth row corresponds to the effects of the drugs on 12373 Candida auris, and the eleventh row corresponds to the effects of the drugs on 12767 Candida auris;

[0024] Figure 2 This is an experiment on the growth of Candida auris by sodium houttuyfonate and new sodium houttuyfonate; A: The antibacterial growth curve of sodium houttuyfonate and new sodium houttuyfonate on C1; B: The antibacterial growth curve of sodium houttuyfonate and new sodium houttuyfonate on C2; C: The antibacterial growth curve of sodium houttuyfonate and new sodium houttuyfonate on C3; D: The antibacterial growth curve of sodium houttuyfonate and new sodium houttuyfonate on C4;

[0025] Figure 3 To detect the effects of sodium houttuyfonate and sodium neohouttuyfonate on the biofilm of Candida auris using the XTT method; A: The effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C1; B: The effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C2; C: The effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C3; D: The effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C4; E: The effect of sodium neohouttuyfonate on the biofilm forming ability of Candida auris C1; F: The effect of sodium neohouttuyfonate on the biofilm forming ability of Candida auris C2; G: The effect of sodium neohouttuyfonate on the biofilm forming ability of Candida auris C3; H: The effect of sodium neohouttuyfonate on the biofilm forming ability of Candida auris C4;

[0026] Figure 4 Calcium fluorescent white (CFW) method was used to detect the effects of sodium houttuyfonate and sodium neohouttuyfonate on the biofilm content of Candida auris; A: Effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C1; B: Effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C2; C: Effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C3; D: Effect of sodium houttuyfonate on the biofilm forming ability of Candida auris C4. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention is clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] In the following examples, sodium houttuyfonate and sodium neohouttuyfonate were used as standard products, which were mixed and dissolved in the prepared RPMI 1640 culture medium to prepare a 2048 μg / mL solution, which was stored at -20°C for later use.

[0029] Example 1 MIC detection of houttuyfonate sodium, new houttuyfonate sodium and fluconazole against Candida auris

[0030] The concentration of each bacterial solution was adjusted to 2×10 3 cells / ml, 100μl of each bacterial solution was diluted in multiples and added to 96-well plates in sequence, and 100μl of bacterial suspension was added to each well; a blank control was set up, and 200μl of RPMI-1640 liquid culture medium was added. The plates were placed at 37℃ and cultured for 48h, and the minimum inhibitory concentration (MIC) of the drugs against the clinically isolated drug-resistant strains of Candida auris C1, C2, C3, C4, 12373 and 12767 was observed by naked eyes. The clinically isolated drug-resistant strains of Candida auris C1, C2, C3, C4, 12373 and 12767 were clinically isolated and donated by Professor Huang Guanghua's research group at Fudan University. Among them, strains C1, C2, C3 and C4 were highly resistant to the commonly used antifungal drug fluconazole (MIC up to 1024μg / ml), while strains 12373 and 12767 were less resistant to fluconazole (MIC up to 128μg / ml). The experiment was repeated three times, and the results are as follows Figure 1 As shown in Table 1, the MIC of fluconazole against C1, C2, C3, and C4 Candida auris was 1024 μg / ml, and the MIC against 12373 and 12767 Candida auris was 128 μg / ml, showing drug resistance. The MIC of houttuynia cordata sodium against C1, C2, C3, and C4 Candida auris was 128 μg / ml, and the MIC against 12373 and 12767 Candida auris was 64 μg / ml, and the MIC of new houttuynia cordata sodium against C1, C2, C3, and C4 Candida auris was 64 μg / ml, and the MIC against 12373 and 12767 Candida auris was 32 μg / ml. It can be seen that the MIC of houttuynia cordata sodium and new houttuynia cordata sodium against each strain is significantly lower than that of fluconazole, indicating a significant inhibitory effect on Candida auris.

[0031] Table 1 MIC values ​​of various drugs for clinical strains of Candida auris

[0032] Candida auris strain name Houttuynia cordata sodium New Houttuynia cordata Sodium Fluconazole C1 128μg / ml 64μg / ml 1024μg / ml C2 128μg / ml 64μg / ml 1024μg / ml C3 128μg / ml 64μg / ml 1024μg / ml C4 128μg / ml 64μg / ml 1024μg / ml 12373 64μg / ml 32μg / ml 128μg / ml 12767 64μg / ml 32μg / ml 128μg / ml

[0033] Example 2 Experiment on the effect of sodium houttuyfonate and new sodium houttuyfonate on the growth of Candida auris

[0034] The study used Candida auris C1, C2, C3 and C4 as research objects. The study was divided into 4 groups: blank group (no drug added), 128μg / ml SH, 64μg / ml SNH, and 128μg / ml Flu group. The concentration of each bacterial solution was adjusted to 2×10 3 cells / ml, placed in a 100ml conical flask, cultured in a constant temperature shaker at 37°C and 200rpm, and the OD600 value of each bacterial solution was detected every 6 hours. The OD600 values ​​of each bacterial solution at different time points were plotted as the antibacterial growth curve of each strain. The experiment was repeated three times.

[0035] The results are as follows Figure 2 As shown, the blank group showed a normal growth curve. Compared with 128μg / ml fluconazole, 128μg / ml houttuynia cordata sodium had a weaker inhibitory effect on the growth of C3 Candida auris, a better inhibitory effect on the growth of C1 Candida auris, and similar inhibitory effects on the growth of C2 and C4 Candida auris. Compared with 128μg / ml fluconazole, 64μg / ml new houttuynia cordata sodium had a better inhibitory effect on the growth of C1, C2, C3 and C4 Candida auris.

[0036] Example 3 Using XTT method to detect the effect of houttuyfonate sodium and new houttuyfonate sodium on the biofilm of Candida auris

[0037] Then, the concentration of each bacterial solution was adjusted to 2.0×10 3 cells / mL. Add 100μL of each bacterial solution to each well of a 96-well plate, incubate at 37°C for 90 minutes, carefully remove the supernatant, add 100μL of PBS buffer to each well, shake gently, and wash 3 times. Add 100μL of RPMI-1640 liquid culture medium to each well, shake gently, and continue to incubate at 37°C for 24h. Carefully remove the supernatant, add 100μL of PBS buffer to each well, shake gently, and wash 3 times. Then add 150μL of XTT in the dark, incubate for 3 hours, and detect the absorbance of each well at 490nm. Repeat the experiment three times.

[0038] The results are as follows Figure 3As shown, the effects of sodium houttuyfonate and sodium neohouttuyfonate on the biofilm formation ability of C1, C2, C3 and C4 Candida auris were detected by XTT reduction method. Compared with 128μg / ml fluconazole, 128μg / ml sodium houttuyfonate had a weaker inhibitory effect on the biofilm formation ability of C1 Candida auris, but had a better inhibitory effect on the biofilm formation of C2, C3 and C4 Candida auris. Compared with 128μg / ml fluconazole, 64μg / ml sodium neohouttuyfonate had a better inhibitory effect on the biofilm formation of C1, C2, C3 and C4 Candida auris.

[0039] Example 4 Calcium fluorescent white (CFW) method was used to detect the effect of sodium houttuyfonate and sodium neohouttuyfonate on the biofilm content of Candida auris

[0040] The concentration of each bacterial solution was adjusted to 2.0×10 3 cells / mL. Blank group (no drug added), 128μg / mlSH, 64μg / mlSNH, 128μg / mlFlu group. Take 2ml of each bacterial solution and place it in a 6-well plate, place it in a 37℃ incubator for 90min, aspirate the supernatant, add RPMI-1640 medium again, culture at 37℃ for 24h, add 500μl CFW staining solution, stain for 5min, discard the supernatant, and observe the biofilm formation under a fluorescence microscope. The experiment was repeated three times.

[0041] The results are as follows Figure 4 As shown, compared with the 128 μg / ml fluconazole group, 128 μg / ml sodium houttuynia cordata and 64 μg / ml sodium houttuynia cordata both had better ability to inhibit the biofilm formation of C1, C2, C3 and C4 Candida auris.

[0042] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. Use of houttuyfonate sodium and / or new houttuyfonate sodium in the preparation of a medicament for preventing and / or treating Candida auris infection.

2. The use according to claim 1, characterized in that: The Candida auris is resistant to at least one antifungal drug selected from azoles, polyenes, echinocandins and nucleoside analogs.

3. The use according to claim 1, characterized in that: The medicine is a medicine for inhibiting the growth of Candida auris.

4. The use according to claim 1, characterized in that: The medicine is a medicine for inhibiting the formation of Candida auris biofilm.

5. The use according to claim 1, characterized in that: The medicine uses houttuyfonate sodium and / or neohouttuyfonate sodium as the only active ingredient.

6. The use according to claim 1, characterized in that: The medicine is a preparation prepared by taking an effective amount of sodium houttuyfonate and / or sodium neohouttuyfonate as active ingredients and adding pharmaceutically acceptable auxiliary materials.

7. The use according to claim 6, characterized in that: The auxiliary materials are any one or a combination of fillers, adhesives, wetting agents, disintegrants, emulsifiers, diluents, lubricants, solvents, cosolvents, solubilizers, stabilizers, surfactants, humectants, antioxidants, pH regulators, colorants, preservatives and fragrances.

8. The use according to claim 6, characterized in that: The preparation is any pharmaceutical dosage form that is pharmaceutically acceptable.

9. The use according to claim 8, characterized in that: The preparation is any one of tablets, capsules, granules, powders, solutions, gels and injections.

10. Use of sodium houttuyfonate and / or new sodium houttuyfonate in the preparation of additives for preventing and controlling Candida auris contamination.

Citation Information

Patent Citations

  • Application of sodium houttuyfonate as synergist of antifungal medicament

    CN101961328A

  • Application of sodium houttuyfonate in preparation of medicine for preventing and treating stress cardiomyopathy

    CN115429781A

  • Antimicrobial / antibacterial medical devices coated with traditional chinese medicines

    US20110076312A1